Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Liminatus Pharma ( (LIMN) ) just unveiled an update.
On May 29, 2025, Liminatus Pharma, Inc. received a notice from the Nasdaq Listing Qualifications Department indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to a delay in filing its Quarterly Report for the period ended March 31, 2025. The company filed the report on June 2, 2025, and by June 3, 2025, it received confirmation of regained compliance, closing the matter.
More about Liminatus Pharma
Average Trading Volume: 34,809
Technical Sentiment Signal: Sell
Current Market Cap: $38.13M
Learn more about LIMN stock on TipRanks’ Stock Analysis page.